Merck Serono to fund $2mn MJFF drive against Parkinson's Disease

Tuesday, December 18, 2007 18:00 IST
New York
http://www.pharmabiz.com/article/det...rticleid=42087

Merck Serono, a Merck KGAA affiliate said it will fund a $2 million initiative to drive treatments for PD-related cognitive dysfunction and mood disorders with Michael J. Fox Foundation.

The Michael J. Fox Foundation for Parkinson's Research has committed up to $2 million for research toward therapies to alleviate Parkinson's-related cognitive dysfunction and mood disorders. The funding is to be awarded under a new initiative, Cognitive Deficits and Mood Disorders in Parkinson's Disease, made possible by generous leadership funding from Merck Serono.

"Most people think of Parkinson's disease as a motor disorder, but time and again, patients tell us that the cognitive and mood-related symptoms of PD -- including depression, anxiety and executive dysfunction -- are some of the most disabling aspects of the disease," said Katie Hood, interim CEO, MJFF. "These symptoms frequently affect patients early in their disease and don't respond to dopamine replacement therapy. With the Cognitive Deficits and Mood Disorders in Parkinson's Disease initiative, we hope to invigorate research and therapeutic development in this very important area."

Cognitive dysfunction, which includes difficulty in planning, sequencing, initiating and sustaining behaviour toward a given goal, and incorporating feedback to make adjustments along the way, is estimated to occur in up to 80 percent of people with PD. Depression is thought to affect up to 50 percent of Parkinson's patients. Anxiety and apathy also are often associated with PD.

Elmar Schnee, president, Merck Serono, commented: "Merck Serono recognizes the urgent need for new therapies to alleviate PD-related mood disorders and cognitive dysfunction, and we look forward to supporting The Michael J. Fox Foundation in pursuit of effective treatments for these under-addressed aspects of Parkinson's disease. Our support of the Foundation is just one example of our commitment to driving the innovative science that will allow every individual to live a fuller and more satisfying life."

"While treatments for classic forms of depression or anxiety have been developed, little evidence exists that they are optimal when used in Parkinson's patients," said Todd Sherer, PhD, the Foundation's vice president, research programs. "Additionally, while information from other fields must be leveraged in pursuing treatments for PD's cognitive and psychiatric symptoms, simple extrapolation of this knowledge to Parkinson's is not possible -- perhaps due to the pathology of PD and its treatments."

Dr. Sherer noted that MJFF and Merck Serono hope, through their innovative partnership, to encourage Parkinson's scientists to collaborate with researchers from other areas, including psychiatry, in order to capitalize on work already done and to obtain different perspectives on cognitive and psychiatric disorders in Parkinson's disease.

The Foundation will accept proposals for clinical research projects or for basic or translational research in relevant preclinical models of PD. Priorities for funding include:

● Novel approaches to understanding the pathophysiology of cognitive dysfunction and psychiatric disorders in PD

● Development and characterization of pre-clinical models for these symptoms

● Examination of the role of cognitive dysfunction and psychiatric disorders in disease onset, progression and prognosis

● Development or validation of tools to predict or assess early development of cognitive dysfunction and psychiatric disorders in PD

● Detailed evaluation of the impact of existing PD treatments on these symptoms

● Pre-clinical and clinical testing of available and experimental treatments for cognitive dysfunction and psychiatric disturbances in PD patients

The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease through an aggressively funded research agenda. To date, the Foundation has funded $100 million in research directly or through partnerships.

Merck Serono International S.A., the new division for innovative small molecules and biopharmaceuticals of Merck, was established following the acquisition of Serono and the integration of its business with the former Merck Ethicals Division. Headquartered in Geneva, Switzerland, Merck Serono discovers, develops, produces and commercializes innovative products to help patients with diseases with unmet needs.